National Institute on Aging (NIA), Harbor Hospital
Baltimore, Maryland, 21225, United States
NCT Number: NCT00105066
The purpose of this study is to evaluate whether the drug Metformin has beneficial effects on the blood vessels of individuals with the Metabolic Syndrome (MeS).
Looking for future studies?
Notify Me21 year–80 year
All sexes
Interventional
Phase 2
Baltimore, Maryland, 21225, United States
Individuals with the Metabolic Syndrome (MeS) are at increased risk for developing cardiovascular diseases. This increased risk may, in part, be related to abnormalities in the blood vessels. MeS is defined as having 3 or more of the following 5 criteria:
Metformin is a medication that is approved by the Food and Drug Administration (FDA) for the treatment of diabetes; however, it can also be safely administered to non-diabetic subjects. We are evaluating whether Metformin reduces the stiffness of blood vessels and improves endothelial function.
This study requires 4 visits to the NIA Clinical Research Center (located on the premises of Harbor Hospital) over a 5-month period. At the initial visit, patients will be given a physical examination with blood and urine tests, and an EKG. They will be randomized into one of two groups; one group will receive Metformin (1700 mg per day), while the other group will receive a placebo. Participants will take the medication for 4 months. Subsequent visits will include additional blood tests, ultrasound and echo exams.
Taking part in this study is entirely voluntary. All testing and medications will be provided at no cost to the participant or their family.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Participants with the Metabolic Syndrome, which is defined as having 3 or more of the following 5 alterations:
Exclusion criteria
850mg tablet once a day for one month, then twice a day for 3 months
Other names: Fortamet®; Glucophage®; Glumetza™; Riomet™
placebo tablet once a day for one month, then twice a day for 3 months
Time frame: Baseline and 4.5 months
Time frame: Baseline and 4.5 months
to evaluate improvement in endothelial function
National Institute on Aging (NIA)
Nih
The Effects of Metformin on Vascular Structure and Function in Subjects With the Metabolic Syndrome (MET Trial)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03206164
Body Weight, Cardiovascular Diseases
Chicago, Illinois, United States
View Trial DetailsNCT00826774
Body Weight, Cardiovascular Diseases
View Trial DetailsNCT06626867
Body Weight, Cardiovascular Diseases
Taipei, Taiwan
View Trial DetailsNCT05685017
Abdominal Obesity, Body Weight
Surabaya, East Java, Indonesia
View Trial Details